Pictet Asset Management Holding SA Sells 33,122 Shares of Bruker Corporation $BRKR

Pictet Asset Management Holding SA trimmed its position in shares of Bruker Corporation (NASDAQ:BRKR) by 22.3% in the 4th quarter, Holdings Channel.com reports. The firm owned 115,121 shares of the medical research company’s stock after selling 33,122 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Bruker were worth $5,423,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Allworth Financial LP grew its holdings in Bruker by 40.6% during the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 257 shares during the period. Spire Wealth Management grew its holdings in Bruker by 85.3% during the third quarter. Spire Wealth Management now owns 1,445 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 665 shares during the period. CWM LLC grew its holdings in Bruker by 49.8% during the fourth quarter. CWM LLC now owns 1,631 shares of the medical research company’s stock valued at $77,000 after purchasing an additional 542 shares during the period. EverSource Wealth Advisors LLC grew its holdings in Bruker by 51.5% during the second quarter. EverSource Wealth Advisors LLC now owns 2,770 shares of the medical research company’s stock valued at $114,000 after purchasing an additional 942 shares during the period. Finally, Jones Financial Companies Lllp grew its holdings in Bruker by 79.7% during the third quarter. Jones Financial Companies Lllp now owns 2,773 shares of the medical research company’s stock valued at $86,000 after purchasing an additional 1,230 shares during the period. 79.52% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on BRKR shares. UBS Group restated a “neutral” rating and set a $49.00 target price on shares of Bruker in a research report on Friday, February 13th. Barclays dropped their target price on Bruker from $50.00 to $45.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 14th. The Goldman Sachs Group dropped their target price on Bruker from $40.00 to $35.00 and set a “sell” rating on the stock in a research report on Friday, February 13th. TD Cowen upgraded Bruker to a “hold” rating in a research report on Monday, April 13th. Finally, Guggenheim dropped their target price on Bruker from $58.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday, March 30th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $49.38.

Insider Buying and Selling at Bruker

In other news, VP Mark Munch sold 2,000 shares of the company’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $39.90, for a total value of $79,800.00. Following the transaction, the vice president owned 128,443 shares of the company’s stock, valued at approximately $5,124,875.70. This represents a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 27.20% of the company’s stock.

Bruker Stock Performance

NASDAQ:BRKR opened at $36.79 on Monday. The company has a market cap of $5.60 billion, a P/E ratio of -245.27, a P/E/G ratio of 2.20 and a beta of 1.12. The stock’s fifty day moving average price is $37.13 and its two-hundred day moving average price is $41.97. Bruker Corporation has a 1 year low of $28.53 and a 1 year high of $56.22. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.73 and a quick ratio of 0.87.

Bruker (NASDAQ:BRKR) last posted its earnings results on Thursday, February 12th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.65 by ($0.06). The company had revenue of $977.20 million for the quarter, compared to analysts’ expectations of $964.61 million. Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.The company’s revenue was down .2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.76 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, analysts expect that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, April 7th. Stockholders of record on Monday, March 23rd were issued a $0.05 dividend. The ex-dividend date of this dividend was Monday, March 23rd. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. Bruker’s dividend payout ratio is presently -133.33%.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.